Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR3C1 | P04150 | 8/20 | 0.68 |
| ▸ | CYP3A4 | P08684 | 7/20 | 0.68 |
| ▸ | PGR | P06401 | 7/20 | 0.68 |
| ▸ | AR | P10275 | 6/20 | 0.68 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.68 |
| ▸ | MAPK1 | P28482 | 3/20 | 0.68 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.68 |
| ▸ | CHRM2 | P08172 | 3/20 | 0.68 |
| ▸ | NPSR1 | Q6W5P4 | 3/20 | 0.68 |
| ▸ | HIF1A | Q16665 | 2/20 | 0.68 |
| ▸ | ADORA3 | P0DMS8 | 2/20 | 0.68 |
| ▸ | CHRM1 | P11229 | 2/20 | 0.68 |
| ▸ | USP2 | O75604 | 2/20 | 0.68 |
| ▸ | THRB | P10828 | 1/20 | 0.68 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.68 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.68 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.68 |
| ▸ | MEN1 | O00255 | 2/20 | 0.67 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.67 |
| ▸ | LMNA | P02545 | 4/20 | 0.65 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Delmadinone Acetate SCHEMBL146081 | 1.00 | NR3C1 (0.68) | NR3C1CYP3A4PGRARSMN1; SMN2 | |
| SCHEMBL6693946 | 0.89 | MEN1 (0.68) | NR3C1CYP3A4PGRARSMN1; SMN2 | |
| SCHEMBL6693949 | 0.89 | MEN1 (0.68) | NR3C1CYP3A4PGRARSMN1; SMN2 | |
| SCHEMBL144012 | 0.83 | PGR (0.62) | NR3C1CYP3A4PGRARSMN1; SMN2 | |
| Chlormadinone Acetate SCHEMBL1460594 | 0.81 | AR (1.00) | NR3C1CYP3A4PGRARSMN1; SMN2 | |
| Chlormadinone Acetate SCHEMBL15046 | 0.81 | AR (1.00) | NR3C1CYP3A4PGRARSMN1; SMN2 | |
| Chlormadinone Acetate SCHEMBL40360 | 0.81 | AR (1.00) | NR3C1CYP3A4PGRARSMN1; SMN2 | |
| Chlormadinone Acetate SCHEMBL11795531 | 0.81 | AR (1.00) | NR3C1CYP3A4PGRARSMN1; SMN2 | |
| Chlormadinone Acetate SCHEMBL4948575 | 0.81 | AR (1.00) | NR3C1CYP3A4PGRARSMN1; SMN2 | |
| Chlormadinone Acetate SCHEMBL29430402 | 0.81 | AR (1.00) | NR3C1CYP3A4PGRARSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1302 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4525938-B1 | RADIOPHARMACEUTICAL COMPLEXES TARGETING PROSTATE-SPECIFIC MEMBRANE ANTIGEN AND ITS COMBINATIONS | BAYER AG (DE) | 2026-03-11 | — | — | EP | claimed |
| US-20250319216-A1 | RADIOPHARMCEUTICAL COMPLEXES TARGETING PROSTATE-SPECIFIC MEMBRANE ANTIGEN AND ITS COMBINATIONS | BAYER AG (DE) | 2025-10-16 | — | — | US | claimed |
| EP-4525938-A1 | RADIOPHARMACEUTICAL COMPLEXES TARGETING PROSTATE-SPECIFIC MEMBRANE ANTIGEN AND ITS COMBINATIONS | Bayer Aktiengesellschaft (DE) | 2025-03-26 | — | — | EP | claimed |
| US-11850306-B2 | Method for drying hydrogel comprising nanofibrillar cellulose and a dried hydrogel comprising nanofibrillar cellulose | UPM-KYMMENE CORPORATION (FI) | 2023-12-26 | — | — | US | claimed |
| WO-2023222557-A1 | RADIOPHARMACEUTICAL COMPLEXES TARGETING PROSTATE-SPECIFIC MEMBRANE ANTIGEN AND ITS COMBINATIONS | BAYER AKTIENGESELLSCHAFT (DE) | 2023-11-23 | — | — | WO | claimed |
| EP-3501543-A1 | METHOD FOR MANUFACTURING VAGINAL DRUG DELIVERY SYSTEMS USING A THREE DIMENSIONAL PRINTER | Delim Cosmetics & Pharma S.r.l. (IT) | 2019-06-26 | — | — | EP | claimed |
| CN-109456382-A | A method of preparing delmadinone acetate | 湖南科瑞生物制药股份有限公司 | 2019-03-12 | — | — | CN | claimed |
| CN-109369763-A | A kind of preparation method of delmadinone acetate product | 湖南科瑞生物制药股份有限公司 | 2019-02-22 | — | — | CN | claimed |
| CN-109369764-A | A kind of preparation method of delmadinone acetate | 湖南科瑞生物制药股份有限公司 | 2019-02-22 | — | — | CN | claimed |
| WO-2016005599-A1 | COMPOSITIONS, METHODS AND USES FOR TREATING GENDER-BIASED IMMUNE DISORDERS | BIOCOPEA LIMITED (GB) | 2016-01-14 | — | — | WO | claimed |
| EP-1501858-A2 | FURTHER SYNTHESES OF CYPROTERONE ACETATE | BOEHRINGER INGELHEIM INTERNATIONAL GmbH (DE) | 2005-02-02 | — | — | EP | claimed |
| US-20040198706-A1 | Methods and formulations for transdermal or transmucosal application of active agents | ANTARES PHARMA, INC. | 2004-10-07 | — | — | US | claimed |
| WO-2004080413-A2 | USES AND FORMULATIONS FOR TRANSDERMAL OR TRANSMUCOSAL APPLICATION OF ACTIVE AGENTS | ANTARES PHARMA IPL AG (CH) | 2004-09-23 | — | — | WO | claimed |
| US-20040024230-A1 | Synthesis of cyproterone acetate | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2004-02-05 | — | — | US | claimed |
| WO-2003092578-A2 | FURTHER SYNTHESES OF CYPROTERONE ACETATE | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2003-11-13 | — | — | WO | claimed |
| EP-1359154-A1 | Further syntheses of cyproterone acetate | BOEHRINGER INGELHEIM INTERNATIONAL GmbH (DE) | 2003-11-05 | — | — | EP | claimed |
| CN-1294519-A | Pharmaceutical composition containing a compound having an activity of promoting the absorption of an active ingredient | INPHARMA SA (CH) | 2001-05-09 | — | — | CN | claimed |
| EP-1073470-A1 | PHARMACEUTICAL COMPOSITIONS CONTAINING COMPOUNDS WITH ACTIVITY FOR THE ENHANCEMENT OF ABSORPTION OF ACTIVE INGREDIENTS | INPHARMA S.A. (CH) | 2001-02-07 | — | — | EP | claimed |
| WO-2000048636-A1 | PHARMACEUTICAL COMPOSITIONS CONTAINING COMPOUNDS WITH ACTIVITY FOR THE ENHANCEMENT OF ABSORPTION OF ACTIVE INGREDIENTS | INPHARMA S.A. (CH) | 2000-08-24 | — | — | WO | claimed |
| WO-1999064941-A1 | TELEPRESENCE SYSTEM AND METHOD FOR THE REMOTE STEERING OF A BOAT | INVERSIONES CALA SALADA, S.L. (ES) | 1999-12-16 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040024230-A1 | Synthesis of cyproterone acetate | CYP17A1, CYP19A1, CYP21A2 | NR3C1 157/4885CYP3A4 57/4885PGR 78/4885 |
| US-20040198706-A1 | Methods and formulations for transdermal or transmucosal application of active agents | SHBG, CYP17A1, NR5A1 | NR3C1 43/4885CYP3A4 2082/4885PGR 74/4885 |
| US-20250319216-A1 | RADIOPHARMCEUTICAL COMPLEXES TARGETING PROSTATE-SPECIFIC MEMBRANE ANTIGEN AND ITS COMBINATIONS | KLK3, FOLH1, PSMA2 | NR3C1 3237/4885CYP3A4 4586/4885PGR 773/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.